ReviewBioMed research international2018
A Comprehensive Review of the Pharmacologic Management of Uterine Leiomyoma.
Review in BioMed research international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The role of mifepristone in managing myoma: a systematic review and meta-analysis of uterine parameters.BMC women's health · 2026Pooled it
- What happens after randomised controlled trials? Uterine fibroids and ulipristal acetate: systematic review and meta-analysis of "real-world" data.Archives of gynecology and obstetrics · 2021Pooled it
- Trial
- Transcutaneous Electrical Acupoint Stimulation Accelerates the Recovery of Patients Undergoing Laparoscopic Myomectomy: A Randomized Controlled Trial.Journal of pain research · 2023Trial
- Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.The New England journal of medicine · 2021Trial
- Diagnostic Performance of Galectin-1 and Mucin-1 in Uterine Tumors: A Case-Control Study.Current issues in molecular biology · 2026Article
- Factors associated with hysterectomy after failure of levonorgestrel-releasing intrauterine system treatment in women with abnormal uterine bleeding.BMC women's health · 2026Article
- Partially Expelled Necrotic Uterine Fibroid After Relugolix Combination Therapy: Case Report and Literature Overview on Adverse Effects of GnRH Antagonists.Case reports in obstetrics and gynecology · 2026Article
- Patterns and Outcomes in the Management of Uterine Fibroids: A Hospital-Based Retrospective Study.Cureus · 2025Article
- Article
- Uterine fibroids with heavy menstrual bleeding stratified by race in a commercial and Medicaid database.AJOG global reports · 2024Article
- Immunohistochemical Expression of the SERPINA3 Protein in Uterine Fibroids.Current pharmaceutical biotechnology · 2024Article
- Levonorgestrel-releasing intrauterine device to treat abnormal uterine bleeding; not one treatment option fits all.Journal of the Turkish German Gynecological Association · 2023Article
- Review
- Pathways of Hypoxia-Inducible Factor (HIF) in the Orchestration of Uterine Fibroids Development.Life (Basel, Switzerland) · 2023Review
- Urinary phytoestrogens and the risk of uterine leiomyomata in US women.BMC women's health · 2023Article
- Importance of Fibrosis in the Pathogenesis of Uterine Leiomyoma and the Promising Anti-fibrotic Effects of Dipeptidyl Peptidase-4 and Fibroblast Activation Protein Inhibitors in the Treatment of Uterine Leiomyoma.Reproductive sciences (Thousand Oaks, Calif.) · 2023Review
- Article
- Treatment Patterns in Patients with Uterine Fibroids With and Without a Diagnosis of Heavy Menstrual Bleeding: Results from a Large U.S. Claims Database.Journal of women's health (2002) · 2023Article
- Accidental Morcellation of Uterine Leiomyosarcoma Influences Relapse Free Survival but Does Not Negatively Influence Overall Survival.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uterine leiomyomata are the most common benign tumors of the gynecologic tract impacting up to 80% of women by 50 years of age. It is well established that these tumors are the leading cause for hysterectomy with an estimated total financial burden greater than $30 billion per year in the United States. However, for the woman who desires future fertility or is a poor surgical candidate, definitive management with hysterectomy is not an optimal management plan. Typical gynecologic symptoms of leiomyoma include infertility, abnormal uterine bleeding (AUB)/heavy menstrual bleeding (HMB) and/or intermenstrual bleeding (IMB) with resulting iron-deficiency anemia, pelvic pressure and pain, urinary incontinence, and dysmenorrhea. The morbidity caused by these tumors is directly attributable to increases in tumor burden. Interestingly, leiomyoma cells within a tumor do not rapidly proliferate, but rather the increase in tumor size is secondary to production of an excessive, stable, and aberrant extracellular matrix (ECM) made of disorganized collagens and proteoglycans. As a result, medical management should induce leiomyoma cells toward dissolution of the extracellular matrix, as well as halting or inhibiting cellular proliferation. Herein, we review the current literature regarding the medical management of uterine leiomyoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.